HAE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Haemonetics Corp (HAE) is not a strong buy at this time for a beginner investor with a long-term focus. While the company's financial performance shows some positive trends, the lack of strong technical indicators, absence of recent positive news, and mixed analyst sentiment suggest that it is better to hold off on buying this stock for now.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 56.86, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 59.091, with resistance at 61.948 and support at 56.234.
Net income increased by 19.33% YoY, EPS rose by 28.38% YoY, and gross margin improved by 6.77% YoY in Q3 2026.
Revenue declined by 2.75% YoY. Analysts have been lowering price targets, and there is no recent positive news or significant insider/hedge fund activity. Stock trend analysis predicts a negative performance in the short term.
In Q3 2026, Haemonetics reported a revenue decline of 2.75% YoY but showed strong profitability improvements with net income up 19.33% YoY, EPS up 28.38% YoY, and gross margin up 6.77% YoY.
Analysts have mixed views. While some maintain Outperform ratings, most have lowered price targets recently. The current price of $60.11 is below the lowest price target of $64, indicating limited upside potential in the near term.
